(Main text of this blog post last updated 6/7/21)
For our most comprehensive and up-to-date EHA21 investor info, click here for our BPIQ EHA21 Investor Hub forum post (BPIQ Pro or free 30 day trial required - click here to sign up and get access)
The annual meeting of the European Hematology Association (EHA21) is being held this year from June 9-17, 2021. In 2020 EHA became virtual with EHA20 hosted online from June 11-21, 2020. This virtual congress had almost 27,000 registrations across 129 countries. Before the pandemic, the yearly congress changed locations across Europe, with the 2019 congress held in Amsterdam. This year, like last year, it is being held virtually due to the pandemic. (https://ehaweb.org/congress/previous-congresses/). The key dates for this year's conference are shown in FIG. 1. In this virtual event, all of the posters will be released on June 11, 2021 at 3AM EST (9AM CEST). Thus, we believe many of those posters will be publicly available to investors, even those who have not registered for EHA21, on company web sites shortly thereafter.
FIG. 1. Key EHA Dates
Click here to view and download the program available on the EHA website indicating specific dates and times of the poster presents, symposiums, and more.
Every year, upon abstract release and as a result of presentations at the conference, some biopharma stocks move significantly because they report important clinical trial updates. As experienced biopharma investors understand, the value of a biopharma company is based in large part on the value of its clinical assets. This value takes into account the likelihood of success of the clinical assets of the underlying company in successfully completing clinical trials. An update to a clinical trial that shows some positive results in safety and especially efficacy, can increase the chance of success for that trial, which increases the value of the asset and the underlying company. The converse is true as well, for disappointing results.
Positive clinical trial results in a single trial can have a significant impact on the underlying stock price. This is especially true for biopharma companies with market caps under $5 billion, who typically have far less clinical and approved assets than larger companies, and thus whose valuation can be more affected by a single drug candidate and trial. The clinical assets of these micro, small and mid-cap cancer biopharma companies are a primary driver for the development of future cancer therapies.
With respect to EHA21 and biomedical conferences in general, a big challenge for investors is to identify in advance, companies that are reporting significant clinical trial updates at the conference. Many presentations provide less significant information with respect to company valuation (e.g. preclinical results or clinical trial design). At BiopharmIQ (BPIQ.com; "BPIQ") we oversee a database of information about clinical assets and their upcoming clinical trial and other catalyst events for virtually every biopharma company with a market cap of between $100M and $5B, which for convenience in this article, we will refer to as smid-cap biopharma companies. Currently, our database has over 500 smid-cap biopharma companies. Our goal at BPIQ is to provide information and education on smid-CAP biopharma companies to level the playing field for all investors, whether retail, professional or institutional.
To this end, our team updated and scoured through our BPIQ database to identify biopharma companies that are presenting clinical trial updates at EHA21. Table 1 (provided at the end of this article) lists those companies in our BPIQ database that are presenting clinical update(s) at EHA21. Table 1 provides the drug candidate name, indication, and clinical phase. For more information including presentation and investor call times, asset technology and targets, stock moves, and links to abstracts and press releases, please visit our BPIQ EHA21 Investor Hub forum post. Plus, in our full EHA21 Investor's Hub forum post we identify the tech area where all the presentations we are tracking for Smid-caps had highly positive stock moves since abstract release.
The question for biopharma investors now with respect to the actual EHA21 virtual meeting being held June 9-17, with almost all posters being released on June 11 at 3AM Eastern, is which stocks or groups of stocks are likely to move upon the release of the EHA21 poster, oral presentation, or associated investor meeting. We plan to continue to analyze the EHA21 abstracts and press releases, to identify those companies that are most likely presenting important clinical updates at poster or oral presentations at EHA21, and plan to update this information on BPIQ.com. In the meantime, the information provided in this article provides an interesting snapshot into the smid-cap biopharma companies that are developing some of our most exciting future medicines. For investors, these companies represent an exciting opportunity for further diligence and possible investment.
Become a BPIQ subscriber now (click here to sign up and get access - free 30 day trial, no credit card) for our most comprehensive and up-to-date EHA21 investor hub/guide: click here. Plus sign up today and you'll get on our weekly catalyst mailing list and get access to our monthly Big-Mover catalyst list where we identify some of the most impactful catalysts events of the month.
Table 1.
BPIQ.com smidCAP biopharma companies presenting clinical updates at EHA21
*Phase for data in abstract. The clinical asset may be in a further advanced stage of clinical trials.